➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
AstraZeneca
Baxter
Medtronic
Harvard Business School

Last Updated: September 24, 2020

DrugPatentWatch Database Preview

Details for Patent: 7,910,605

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,910,605 protect, and when does it expire?

Patent 7,910,605 protects WAKIX and is included in one NDA.

This patent has twenty-four patent family members in twelve countries.

Summary for Patent: 7,910,605
Title:Non-imidazole alkylamines as histamine H.sub.3- receptor ligands and their therapeutic applications
Abstract: Use of a compound of formula (A), wherein: ##STR00001## W is a residue which imparts antagonistic and/or agonistic activity at histamine H.sub.3-receptors when attached to an imidazole ring in 4(5) position; R.sup.1 and R.sup.2 may be identical or different and represent each independently a lower alkyl or cycloalkyl, or taken together with the nitrogen atom to which they are attached, a saturated nitrogen-containing ring (i) as defined, a non-aromatic unsaturated nitrogen-containing ring (ii) as defined, a morpholino group, or a N-substituted piperazino group as defined for preparing medicaments acting as antagonists and/or agonists at the H.sub.3-receptors of histamine.
Inventor(s): Schwartz; Jean-Charles (Paris, FR), Arrang; Jean-Michel (Dourdon, FR), Garbarg; Monique (Paris, FR), Lecomte; Jeanne-Marie (Paris, FR), Ligneau; Xavier (Paris, FR), Schunack; Walter G. (Berlin, DE), Stark; Holger (Berlin, DE), Ganellin; Charon Robin (Welwyn, GB), Leurquin; Fabien (London, GB), Elz; Sigurd (Berlin, DE)
Assignee: Societe Civile Bioprojet (Paris, FR)
Application Number:11/478,682
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,910,605

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Harmony WAKIX pitolisant hydrochloride TABLET;ORAL 211150-001 Aug 14, 2019 RX Yes No   Start Trial   Start Trial METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY   Start Trial
Harmony WAKIX pitolisant hydrochloride TABLET;ORAL 211150-002 Aug 14, 2019 RX Yes Yes   Start Trial   Start Trial METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,910,605

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
98401944Jul 29, 1998
98403351Dec 31, 1998

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Mallinckrodt
Express Scripts
Dow
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.